A carregar...
Characterization of T‐DM1‐resistant breast cancer cells
The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab an...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7314699/ https://ncbi.nlm.nih.gov/pubmed/32583565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.617 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|